Search results
Novo’s Blockbuster Ozempic Among FTC’s Latest Patent Targets
Bloomberg Law· 2 hours agoOzempic and Victoza are among 20 branded drugs the Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved drugs in an effort ...
FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
Forbes· 14 hours agoThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca,...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 4 hours agoSome observers have said it is unclear...s scrutiny of the Orange Book will be enough to boost ...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
CNBC· 56 minutes agoThe Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents...
Wisconsin high school football coach unable to get chemo due to shortage dies at 60
NBC News via Yahoo News· 3 hours ago“A number of firms are going either out of business, or they’re having quality problems because...
These Are the Drugs America Is Running Short On
247wallst.com· 1 day agoDrug shortages in America are the result of supply line challenges, profit-based operations, and company closures.
Weight loss drugs like Wegovy have taken the country by storm. But who can afford them?
USA TODAY via Yahoo Finance· 5 days agoDrugmakers say they price drugs to recoup years of research and development costs. They often also...
Mark Cuban has a simple question for CVS’s drug middleman: Why don’t you publish your prices?
Ohio Capital Journal via Yahoo News· 4 days agoBusinessman and TV personality Mark Cuban has a seemingly straightforward question for the huge drug...
Sanofi profit slips on generic competition and currency effects By Reuters
Investing.com· 6 days agoOperating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above...
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks via Yahoo Finance· 6 days agoBiogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key...